DiaMedica Therapeutics is a biopharmaceutical company which engages in the development of treatments for neurological and kidney diseases. The Company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia.
Net income (FY, 2019)
EBIT (FY, 2019)
Market capitalization (26-Mar-2020)
Closing stock price (26-Mar-2020)
|Company Name||Date||Deal Size|
|DiaMedica Australia Pty Ltd|
DiaMedica Therapeutics has 1.61k Twitter Followers. The number of followers has decreased 0.1% month over month and decreased 0.9% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was DiaMedica Therapeutics founded?
DiaMedica Therapeutics was founded in 2000.
Who are DiaMedica Therapeutics key executives?
DiaMedica Therapeutics's key executives are Richard Pilnik, Michael Giuffre and Sydney Gilman.
How many employees does DiaMedica Therapeutics have?
DiaMedica Therapeutics has 26 employees.
Who are DiaMedica Therapeutics competitors?
Competitors of DiaMedica Therapeutics include NeuroPace, Ampio Pharmaceuticals and Inovio Pharmaceuticals.
Where is DiaMedica Therapeutics headquarters?
DiaMedica Therapeutics headquarters is located at 2 Carlson Parkway, Suite 260, Minneapolis.
Where are DiaMedica Therapeutics offices?
DiaMedica Therapeutics has an office in Minneapolis.
How many offices does DiaMedica Therapeutics have?
DiaMedica Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies